| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.RADONC.2007.10.017 |
| P698 | PubMed publication ID | 18022720 |
| P2093 | author name string | Ken Takeda | |
| Kenji Nemoto | |||
| Masashi Koto | |||
| Masatoshi Mitsuya | |||
| Shogo Yamada | |||
| Yoshihiro Ogawa | |||
| Yoshihiro Takai | |||
| Chiaki Takahashi | |||
| Haruo Matsushita | |||
| Keith R Britton | |||
| Kenji Takai | |||
| Kei-ichi Jingu | |||
| P433 | issue | 3 | |
| P921 | main subject | non-small-cell lung carcinoma | Q3658562 |
| P304 | page(s) | 429-434 | |
| P577 | publication date | 2007-11-26 | |
| P1433 | published in | Radiotherapy and Oncology | Q14251029 |
| P1476 | title | A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer | |
| P478 | volume | 85 |
| Q47877896 | A phase I/II study on stereotactic body radiotherapy with real-time tumor tracking using CyberKnife based on the Monte Carlo algorithm for lung tumors |
| Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
| Q37251404 | An evaluation of planning techniques for stereotactic body radiation therapy in lung tumors |
| Q87410539 | Analysis of biologically equivalent dose of stereotactic body radiotherapy for primary and metastatic lung tumors |
| Q26823670 | Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy? |
| Q40608540 | Assessing the Need for Adjuvant Chemotherapy After Stereotactic Body Radiation Therapy in Early-stage Non-small Cell Lung Carcinoma |
| Q37727823 | Bringing the heavy: carbon ion therapy in the radiobiological and clinical context |
| Q37522740 | Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy |
| Q36481633 | Clinical outcome of stereotactic body radiotherapy for primary and oligometastatic lung tumors: a single institutional study with almost uniform dose with different five treatment schedules |
| Q34202715 | Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size |
| Q36382039 | Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis |
| Q38914996 | Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis. |
| Q38240581 | Comparison of therapeutic results from radiofrequency ablation and stereotactic body radiotherapy in solitary lung tumors measuring 5 cm or smaller |
| Q34366518 | Correlation between tumor size and blood volume in lung tumors: a prospective study on dual-energy gemstone spectral CT imaging |
| Q37876669 | Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy |
| Q36451644 | Dosimetric evaluation of the feasibility of stereotactic body radiotherapy for primary lung cancer with lobe-specific selective elective nodal irradiation |
| Q37645201 | Emerging treatment options in the management of non-small cell lung cancer. |
| Q37301068 | Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy |
| Q35074232 | Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy |
| Q38233871 | Is stereotactic ablative radiotherapy an alternative to surgery in operable stage I non-small cell lung cancer? |
| Q64997326 | Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age. |
| Q50428041 | Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy |
| Q41888159 | Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group |
| Q61804648 | Optimizing immobilization, margins, and imaging for lung stereotactic body radiation therapy |
| Q33826696 | Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors |
| Q34372246 | Outcomes of accelerated hypofractionated radiotherapy in stage i non-small-cell lung cancer. |
| Q26851601 | Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients |
| Q37693407 | Pro-apoptotic Noxa is involved in ablative focal irradiation-induced lung injury |
| Q36524133 | Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis |
| Q41546002 | Proton beam therapy in non-small cell lung cancer: state of the art. |
| Q35734103 | Radiation-induced rib fracture after stereotactic body radiotherapy with a total dose of 54-56 Gy given in 9-7 fractions for patients with peripheral lung tumor: impact of maximum dose and fraction size |
| Q57875955 | Radiothérapie en conditions stéréotaxiques des patients inopérables |
| Q40010886 | Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study |
| Q37566614 | Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer |
| Q42384628 | SBRT versus lobectomy in stage I NSCLC: knowns, unknowns and its interpretation |
| Q60912983 | Stereotactic body radiation therapy for non-small cell lung cancer: A review |
| Q64096283 | Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications |
| Q38560967 | Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients |
| Q84146368 | Stereotactic body radiotherapy for lung tumors at the pulmonary hilum |
| Q42033188 | Stereotactic body radiotherapy for small lung tumors in the University of Tokyo Hospital |
| Q82084588 | Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer: a multicenter study |
| Q36734816 | Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer |
| Q90591596 | Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer |
| Q47153199 | Synchronous non small cell lung cancer nodules treated with stereotactic body radiation therapy (SBRT). |
| Q37777872 | The Tumor Microenvironment in Non–Small-Cell Lung Cancer |
| Q49333936 | The evolution of proton beam therapy: Current and future status |
| Q34366525 | The impact of abdominal compression on outcome in patients treated with stereotactic body radiotherapy for primary lung cancer |
| Q47734152 | The impact of technology on the changing practice of lung SBRT. |
| Q37589200 | Treatment advances for medically inoperable non-small-cell lung cancer: emphasis on prospective trials |
| Q58584561 | Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation Therapy |
| Q38930349 | Treatment: Radiation Therapy |
| Q39015830 | Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models. |
| Q38172228 | What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer |
| Q53288899 | [Stereotactic body radiaton therapy for 15 patients with small lung neoplasms]. |
Search more.